<DOC>
	<DOCNO>NCT01052818</DOCNO>
	<brief_summary>The purpose study evaluate association number circulate tumor cell response treatment non small-cell lung cancer patient</brief_summary>
	<brief_title>Therapeutic Prognostic Impact Circulating Tumor Cells Peripheral Blood Patients With Non Small-cell Lung Cancer</brief_title>
	<detailed_description>In spite technological advantage diagnosis treatment , lung cancer remain one deadly malignant neoplasia . Moreover , marker monitor response treatment . The objective study associate number circulate tumor cell ( CTC ) treatment correlate tumor response rate , progression-free survival overall survival .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplastic Cells , Circulating</mesh_term>
	<criteria>Histopathologic diagnosis non smallcell lung cancer Clinical stage IV ECOG functional status 0 1 No renal function alteration ( GFR &gt; 50 % ) No hepatic function alteration ( ALT AST less 2 time normal value ) Leucocytes 2,000/mcl Hemoglobin 10mg/dL Platelets 100,000/mcl Nonadvanced disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Non small-cell lung cancer</keyword>
	<keyword>Circulating tumor cell</keyword>
	<keyword>Carcinoembryonic antigen</keyword>
	<keyword>Cytokeratin</keyword>
</DOC>